These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 19789124)

  • 1. [From old to new anticoagulants: the role of the biologist].
    Samama M; Depasse F
    Ann Biol Clin (Paris); 2009; 67(5):525-34. PubMed ID: 19789124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Two new anticoagulants available in 2010--Dabigatran Etexilate and Rivaroxaban: expected progresses--raised problems].
    Samama M; Conard J; Horellou MH; Le Flem L; Guinet C; Depasse F
    Ann Pharm Fr; 2010 Nov; 68(6):359-69. PubMed ID: 21073994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Old versus new anticoagulants: focus on pharmacology.
    Benmira S; Banda ZK; Bhattacharya V
    Recent Pat Cardiovasc Drug Discov; 2010 Jun; 5(2):120-37. PubMed ID: 20337579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
    Dumont B; Faille D; Ajzenberg N
    Med Sci (Paris); 2011 May; 27(5):493-500. PubMed ID: 21609670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond unfractionated heparin and warfarin: current and future advances.
    Hirsh J; O'Donnell M; Eikelboom JW
    Circulation; 2007 Jul; 116(5):552-60. PubMed ID: 17664384
    [No Abstract]   [Full Text] [Related]  

  • 7. Routine coagulation assays underestimate levels of antithrombin-dependent drugs but not of direct anticoagulant drugs in plasma from patients with cirrhosis.
    Potze W; Arshad F; Adelmeijer J; Blokzijl H; van den Berg AP; Porte RJ; Lisman T
    Br J Haematol; 2013 Dec; 163(5):666-73. PubMed ID: 24219333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylaxis of venous thromboembolism: low molecular weight heparin compared to the selective anticoagulants rivaroxaban, dabigatran and fondaparinux.
    Welzel D; Hull R; Fareed J
    Int Angiol; 2011 Jun; 30(3):199-211. PubMed ID: 21617603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticoagulation with rivaroxaban: covering a broad spectrum of thromboembolic disease.
    Schellong S
    Expert Rev Cardiovasc Ther; 2013 Jul; 11(7):817-28. PubMed ID: 23895025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New oral anticoagulants: prospects].
    Fiessinger JN
    Rev Prat; 2010 May; 60(5):613-6. PubMed ID: 20564841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The novel anticoagulants: entering a new era.
    Bounameaux H
    Swiss Med Wkly; 2009 Feb; 139(5-6):60-4. PubMed ID: 19204837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New oral anticoagulant drugs in cardiovascular disease.
    Ahrens I; Lip GY; Peter K
    Thromb Haemost; 2010 Jul; 104(1):49-60. PubMed ID: 20539909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development.
    Ufer M
    Thromb Haemost; 2010 Mar; 103(3):572-85. PubMed ID: 20135071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Laboratory testing for the new oral anticoagulants: a review of current practice.
    Favaloro EJ; Bonar R; Butler J; Marsden K
    Pathology; 2013 Jun; 45(4):435-7. PubMed ID: 23635821
    [No Abstract]   [Full Text] [Related]  

  • 15. Rivaroxaban for the prevention and treatment of venous thromboembolism.
    Turpie AG
    Fundam Clin Pharmacol; 2012 Feb; 26(1):33-8. PubMed ID: 21851388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dabigatran, rivaroxaban, apixaban, argatroban and fondaparinux and their effects on coagulation POC and platelet function tests.
    Eller T; Busse J; Dittrich M; Flieder T; Alban S; Knabbe C; Birschmann I
    Clin Chem Lab Med; 2014 Jun; 52(6):835-44. PubMed ID: 24406289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New anticoagulants for atrial fibrillation.
    Sobieraj-Teague M; O'Donnell M; Eikelboom J
    Semin Thromb Hemost; 2009 Jul; 35(5):515-24. PubMed ID: 19739042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel anticoagulants: new evidence for emerging drugs and their potential application in major lower limb surgery.
    Nikolaou VS; Harwood PJ; Karadimas EJ; Tan HB; Giannoudis PV
    Curr Vasc Pharmacol; 2011 Jan; 9(1):54-60. PubMed ID: 21044021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation?
    Hellwig T; Gulseth M
    Ann Pharmacother; 2013 Nov; 47(11):1478-87. PubMed ID: 24259602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement.
    Freyburger G; Macouillard G; Labrouche S; Sztark F
    Thromb Res; 2011 May; 127(5):457-65. PubMed ID: 21277622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.